Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive MyelofibrosisClaire Harrison, John Mascarenhas, Aaron T. Gerds et al.|Future Oncology|2022Cited by 40